




## Supporting Materials

## **Crystal Structures of Antiarrhythmic drug Disopyramide and its Salt with Phthalic acid**

Majid Ismail Tamboli<sup>1, †</sup>, Yushi Okamoto<sup>1</sup>, Yohei Utusmi<sup>1</sup>, Takayuki Furuishi<sup>1, †</sup>, Siran Wang<sup>1</sup>, Daiki Umeda<sup>1</sup>, Okky Dwichandra Putra<sup>1, \*</sup>, Kaori Fukuzawa<sup>1</sup>, Hidehiro Uekusa<sup>2</sup> and Etsuo Yonemochi<sup>1,\*</sup>

- <sup>1</sup> Department of Physical Chemistry, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, 2-4-41 Ebara, Shinagawa-ku, Tokyo, 142-8501, Japan
- <sup>2</sup> Department of Chemistry, School of Science, Tokyo Institute of Technology, Tokyo 152-8551, Japan
- \* Correspondence: dwichandraputra@yahoo.com; Tel.: +81-3-5498-5148 (O.P.); e-yonemochi@hoshi.ac.jp; Tel.: +81-3-5498-5048 (Y.E.)
- **†** Co-first author, these authors contributed equally to this work.



**Figure 1.** PXRD patterns of (**a**) commercial DPA; (**b**) DPA crystal, (**c**) simulated DPA, (**d**) PA, (**e**) DPA\_PA salt and (**f**) simulated DPA\_PA salt.




Figure S2. FT-IR spectra of (a) commercial DPA; (b) DPA crystal, (c) PA, (d) DPA\_PA salt.




Figure S3. DSC profiles of (a) commercial DPA, (b) DPA crystal, (c) PA, (d) DPA\_PA




Figure S4. TG curves of commercial DPA (yellow), DPA crystal (gray), PA (orange), DPA\_PA salt (blue)